Malaysia Pharmaceuticals and Healthcare Report Q2 2012

Business Monitor International
March 20, 2012
106 Pages - SKU: BMI3816792
Countries covered: Malaysia

BMI View: Malaysia’s longer term potential as an attractive pharmaceutical market will remain shaped by theprevailing economic conditions and the export situation, which are crucial for the country’s overall economicdevelopment and thus also the availability of individual funding for medicines, given the high out-of-pocketcontribution to healthcare. Nevertheless, volume demand will continue to grow on the back of demographic andepidemiological changes, supported by the expansion of modernisation of healthcare provision in both public andprivate sectors.

Headline Expenditure Projections

.. Pharmaceuticals: MYR4.92bn (US$1.61bn) in 2011 to MYR5.23bn (US$1.64bn) in 2012; +5.9% in localcurrency and +2.1% in US dollars. Forecast down slightly from Q212 due to macroeconomic factors.

.. Healthcare: MYR38.93bn (US$12.73bn) in 2011 to MYR41.32bn (US$13.01bn) in 2012; +6.1% in localcurrency and +2.3% in US dollars. Forecast down slightly from Q212 due to macroeconomic factors.

.. Medical devices: MYR3.82bn (US$1.25bn) in 2011 to MYR4.00bn (US$1.26bn) in 2012; +4.9% in localcurrency and +1.1% in US dollars. Forecast broadly unchanged from Q212.

Business Environment Rating: In our latest proprietary Pharmaceutical Risk/Reward Rating (RRR) matrix for AsiaPacific, Malaysia ranks in an unchanged position 8 out of the 18 countries surveyed regionally. The country’srewards are considered modest at best, given the low per capita spending on pharmaceuticals, but its matrix positioncontinues to be supported by the strong risk scores.

Key Trends & Developments

.. In January 2012, Malaysian Minister of Health Liow Tiong Lai stated that a dengue fever vaccine will beavailable in the country by 2014 or 2015. The health ministry is set to enter the third phase of clinical trialson a vaccine by the end of 2012. Liow said the ministry achieved success during the second phase of trials,which involved monitoring about 2,000 people from Penang and Putrajaya. The ministry and Frenchdrugmaker Sanofi have been developing the vaccine to treat dengue.

BMI Economic View: Despite a better-than-expected real GDP growth reading of 5.2% year-on-year (y-o-y) inQ411, we are happy to maintain our below consensus view on the Malaysian economy in 2012. Our core view thatcooling global demand will continue to drag on production of cyclical goods – including industrial metals andelectrical and electronic components – means that we expect manufacturing sector growth to remain weak goingforward. Accordingly, we expect Malaysia's real GDP growth to come in at a subdued 3.3% in 2012, compared toconsensus forecast of 4.2%.

BMI Political View: The opposition Democratic Action Party (DAP) has proposed new measures aimed ataddressing corruption. Some of the key measures include a ban on political parties' involvement in businesses and theadoption of an open tender system for government contracts. DAP Secretary General Lim Guan Eng said thateconomic losses due to corruption are close to estimates published by Washington-based financial watchdog GlobalFinancial Integrity (GFI) at MYR1.1bn (US$0.3bn) annually. We believe that the move will put further pressure onthe ruling Barisan Nasional to speed up efforts to tackle corruption.



More Manufacturing, Packaging & Detailing reports by Business Monitor International

Tanzania Pharmaceuticals and Healthcare Report - Q4 2014 by Business Monitor International
Tanzania Pharmaceuticals and Healthcare Report - Q4 2014BMI View: The government's healthcare sector development plans could be seriously derailed. This is dueto expenditure figures ...
Taiwan Pharmaceuticals and Healthcare Report - Q4 2014 by Business Monitor International
Taiwan Pharmaceuticals and Healthcare Report - Q4 2014BMI View: While Taiwan's intellectual property regime has some deficiencies, drug pricing remains thekey issue of concern ...
Romania Pharmaceuticals and Healthcare Report - Q4 2014 by Business Monitor International
Romania Pharmaceuticals and Healthcare Report - Q4 2014BMI View: Sales data have provided support to our earlier view that Romania's pharmaceutical marketrecovery would be ...
Puerto Rico Pharmaceuticals and Healthcare Report - Q4 2014 by Business Monitor International
Puerto Rico Pharmaceuticals and Healthcare Report - Q4 2014BMI View: Puerto Rico will continue to attract investment from multinational pharmaceutical companiesdue to its tax ...
See all reports like this >>

More Malaysia Manufacturing, Packaging & Detailing reports

Malaysia Healthcare Outlook by Frost & Sullivan
Malaysia Healthcare Outlook Methodology and Scope This research service focuses on the Malaysian healthcare industry, providing a detailed overview of the investment scenario in particular. ...
Pharmaceuticals and Healthcare Report - Malaysia - Q3 2014 by Business Monitor International
Malaysia Pharmaceuticals and Healthcare Report Q3 2014BMI View: We remain generally optimistic towards Malaysia's commitment to provide better quality andaccess to healthcare, as the government ...
Malaysia Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Malaysia Pharmaceuticals and Healthcare Report Q2 2014BMI View: Malaysia's pharmaceutical and healthcare markets continue to show strong growth, and thegovernment's 2014 budget allocation for the ...
Malaysia Healthcare Industry 1H13 by Emerging Markets Direct Reports
Malaysia: Healthcare covers the country's healthcare industry overview in terms of healthcare services, health human resources, healthcare expenditure and private market size. It also covers ...
See all reports like this >>

More Malaysia reports

D&B Country RiskLine Report: Malaysia by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
PCs – Malaysia – a snapshot (2010) by Mintel - Snapshots
PCs in Malaysia by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers desktop ...
See all reports like this >>

 

SELECT A LICENSE

    Report with 3 quarterly updates  USD 1,175  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!